Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Lucia Y Chen, Michael Amatangelo, Adolfo Aleman, Oliver Van Oekelen, Tania Nevers, Yongliang Sun, William E. Pierceall, Katerina Kappes, Anna Blangiardo, Sundar Jagannath, Cesar Rodriguez, Samir Parekh

Blood (2024) 144 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2024-211651

Published: 2024

Journal Articles

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Tracy T. Chow, Nicholas Stong, Saleh Tamim, Chad C. Bjorklund, Antonina Kurtova, Keyur Desai, Joseph T. Hadala, Cynthia Donahue, Phillip Koo, Yue Zhu, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo

Blood (2024) 144 (Supplement 1): 3261.

https://doi.org/10.1182/blood-2024-199019

Published: 2024

Journal Articles

Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial

Michael Amatangelo, Nicholas Stong, Paulo Maciag, Anna Sureda Balari, Niels W.C.J. van de Donk, Sagar Lonial, Anita K. Gandhi

Blood (2024) 144 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2024-199016

Published: 2024

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Peilin Ma, Vinidhra Sridharan, Krista Wollerman, Debjani Dutta, Ram Kumar Singh, Sambuddo Mukherjee, Chad C. Bjorklund, Patrick R Hagner, Michael Amatangelo, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2023-189423

Published: 2023

Journal Articles

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Michael Amatangelo, Erin Flynt, Nicholas Stong, Maria Ortiz, Pradipta Ray, Maria Wang, Niels W.C.J. van de Donk, Sagar Lonial, Aparna Raval, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2023-178912

Published: 2023

Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3318.

https://doi.org/10.1182/blood-2023-178881

Published: 2023

Journal Articles

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Sagar Lonial, Al-Ola Abdallah, Faiz Anwer, Ashraf Z. Badros, Manisha Bhutani, Abdullah Khan, Brea Lipe, Albert Oriol, Darrell White, Michael Amatangelo, Kexin Jin, Mark Masin, Vi Nguyen, Alpesh Amin, Paulo Maciag, Niels WCJ Van De Donk

Blood (2022) 140 (Supplement 1): 4398–4400.

https://doi.org/10.1182/blood-2022-158180

Published: 2022

Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 1366–1368.

https://doi.org/10.1182/blood-2022-157945

Published: 2022

Journal Articles

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Jian Kang, Hsiling Chiu, Archana Mukhopadhyay, Krista Wollerman, Michael Pourdehnad, Patrick Hagner, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2021-153907

Published: 2021

Journal Articles

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Blood (2021) 138 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2021-147812

Published: 2021

Journal Articles

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Alessandro Lagana, Sarah Gooding, Sundar Jagannath, William E. Pierceall, Udo Oppermann, Samir Parekh, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 730.

https://doi.org/10.1182/blood-2021-151542

Published: 2021

Journal Articles

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

Chad C Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, Tiziana Civardi, Jessica Katz, Paulo Maciag, Patrick Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2021-153994

Published: 2021

Journal Articles

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137743

Published: 2020

Journal Articles

Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-137710

Published: 2020

Journal Articles

Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137667

Published: 2020

Journal Articles

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Danny V Jeyaraju, Ekta Kumari, Michael Amatangelo, Chad C. Bjorklund, Chih-Chao Hsu, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 4406.

https://doi.org/10.1182/blood-2019-129181

Published: 2019

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

https://doi.org/10.1182/blood-2019-126828

Published: 2019

NARROW

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2 /M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001

Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only